Meeting
2022 ASCO Genitourinary Cancers Symposium
A multicenter real-world study reviewing systemic anticancer treatment choices and drop off rates between treatment lines for metastatic renal cell carcinoma in the United Kingdom: In the immunotherapy era.
Authors
John McGrane
Royal Cornwall Hospital, Truro, United Kingdom
John McGrane , Ricky Frazer , Amarnath Challapalli , Gihan Ratnayake , Anna Lydon , Dominique Siobhan Parslow , Anand Sharma , Niall Moon , Senjuti Gupta , Sara Walters , Megan Driver , Rebecca Alexander , Sarah Kingdon , Muhammad Khan , Amit Bahl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 358)
DOI
10.1200/JCO.2022.40.6_suppl.358
Abstract #
358
Poster Bd #
G6
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
First Author: Igor Stukalin
Poster
2024 ASCO Genitourinary Cancers Symposium
Treatment patterns and costs among patients with metastatic renal cell carcinoma (mRCC) in the United States: A real-world study using integrated claims and clinical data.
First Author: Daniel M. Geynisman
Poster
2023 ASCO Genitourinary Cancers Symposium
Multi-centre review of systemic anti-cancer prescribing patterns and treatment drop off rates in the United Kingdom 2018-2021.
First Author: John McGrane
Poster
2023 ASCO Genitourinary Cancers Symposium
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study.
First Author: Marco Stellato